Clinical and experimental nephrology · 2026
Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saito Chie, Mase Kaori, Ishibashi Shun, Harada Takuya, Tsunoda Ryoya, Usui Toshiaki, Simizu Tatsuya, Nagai Kei, Ohkubo Reiko, Morito Naoki, Hagiwara Masahiro, Kai Hirayasu, Usui Joichi, Yamagata Kunihiro
Аннотация
BACKGROUND: Cilostazol has antiplatelet and vasodilatory properties and may provide renoprotective and cardiovascular benefits; however, its effects in patients with advanced chronic kidney disease (CKD) remain unclear.
METHODS: This prospective pilot study enrolled 12 patients with advanced CKD due to nephrosclerosis (7 men, 5 women; mean age 65.3 ± 11.0 years). Patients were randomly assigned to receive cilostazol 200 mg/day plus aspirin 100 mg/day (Group C, n = 6) or aspirin 100 mg/day alone (Group A, n = 6). Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin and para-aminohippuric acid clearance at baseline and after 1 year. Renal outcomes and complications were evaluated, followed by long-term observation until initiation of renal replacement therapy (RRT).
RESULTS: Baseline GFR and RPF were comparable between groups. After 1 year, GFR increased in 4 of 6 patients in Group C but declined in all patients in Group A. Mean GFR decreased significantly in Group A but not in Group C. Although estimated GFR declined in both groups, the annual rate of decline was significantly slower in Group C than in Group A (- 2.72 vs. - 3.84 mL/min/1.73 m2/year). RPF and urinary protein levels showed no significant changes in either group. Over a mean follow-up of 6.7 years, RRT was initiated in 2 patients in Group C and 4 in Group A. Two cerebral infarctions occurred in Group A, whereas no cardiovascular events occurred in Group C.
CONCLUSION: Cilostazol may slow short-term renal function decline and offer long-term cardiovascular protection in patients with advanced CKD. Further studies are needed to determine its role in preventing long-term renal deterioration.
METHODS: This prospective pilot study enrolled 12 patients with advanced CKD due to nephrosclerosis (7 men, 5 women; mean age 65.3 ± 11.0 years). Patients were randomly assigned to receive cilostazol 200 mg/day plus aspirin 100 mg/day (Group C, n = 6) or aspirin 100 mg/day alone (Group A, n = 6). Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin and para-aminohippuric acid clearance at baseline and after 1 year. Renal outcomes and complications were evaluated, followed by long-term observation until initiation of renal replacement therapy (RRT).
RESULTS: Baseline GFR and RPF were comparable between groups. After 1 year, GFR increased in 4 of 6 patients in Group C but declined in all patients in Group A. Mean GFR decreased significantly in Group A but not in Group C. Although estimated GFR declined in both groups, the annual rate of decline was significantly slower in Group C than in Group A (- 2.72 vs. - 3.84 mL/min/1.73 m2/year). RPF and urinary protein levels showed no significant changes in either group. Over a mean follow-up of 6.7 years, RRT was initiated in 2 patients in Group C and 4 in Group A. Two cerebral infarctions occurred in Group A, whereas no cardiovascular events occurred in Group C.
CONCLUSION: Cilostazol may slow short-term renal function decline and offer long-term cardiovascular protection in patients with advanced CKD. Further studies are needed to determine its role in preventing long-term renal deterioration.